SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2012, Vol. 10 ›› Issue (1): 100-108.doi: 10.3736/jcim20120115

Special Issue: Traditional Chinese Medicine

• Original Experimental Research • Previous Articles     Next Articles

Dynamic changes of laboratory parameters of rats with type 2 diabetes and insulin resistance: defining their role in development of traditional Chinese medicine syndrome

Liu Yue1,Xie Ming2(),Zhang Ye3   

  1. 1. Center of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
    2. State Key Department of Formulaology, Beijing University of Chinese Medicine, Beijing 100029, China
    3. Department of Formulaology, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, Henan Province, China
  • Received:2011-08-17 Accepted:2011-09-07 Online:2012-01-20 Published:2018-09-21
  • Contact: Xie Ming E-mail:xieming603@263.net

RichHTML

PDF (PC)

171

Like

OBJECTIVE: To observe the development of Chinese medicine syndromes of rats with type 2 diabetes and insulin resistance by detecting dynamic changes of laboratory parameters.METHODS: A total of 110 male Sprague-Dawley rats were randomly divided into control group (n=50) and model group (n=60) to observe the correlation between laboratory parameter changes and development of Chinese medicine syndromes. A rat model of type 2 diabetes and insulin resistance was established by feeding rats with high-calorie and high-fat diet together with peritoneal injection of streptozocin (30 mg/kg, once). At the end of 0, 6, 8, 10 and 12 weeks, 10 rats were randomly selected form each group and blood was taken from common carotid artery to detect contents of total cholesterol (TC), triacylglycerol (TAG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and leptinin serum, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) contents in plasma and whole blood and plasma viscosities.RESULTS: Compared with the control group, concentrations of TNF-α, IL-6, leptin and cAMP and ratio of cAMP/cGMP increased and content of cGMP decreased markedly from the 6th week to the 12th week. Concentrations of TC, TAG and LDL-C increased from the 8th week to the 12th week, while HDL-C decreased from the 10th week to the 12th week. Whole blood and plasma viscosity values under different shear rates increased significantly from the 10th week to the 12th week.CONCLUSION: Based on the understanding of markers which have close relationship with Chinese medicine syndromes of dual deficiency of qi and yin, turbid phlegm and blood stasis, combining with the dynamic changes of appearance behavior and laboratory parameters of this animal experiment, the authors speculate the development characteristics of Chinese medicine syndromes in rats with type 2 diabetes. The dynamic progress of Chinese medicine syndromes and pathology varies from dual deficiency of qi and yin to dual deficiency of qi and yin with turbid phlegm, and at last to the combination of dual deficiency of qi and yin, turbid phlegm and blood stasis.

Key words: diabetes mellitus, type 2, insulin resistant, models, animal, syndrome, rats

Table 1

Content of serum total cholesterol in two groups at different time points ($\bar{x}$±s, mmol/L)"

Group n Total cholesterol
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 0.89±0.01 0.91±0.07 0.92±0.03 1.01±0.03 1.02±0.19
Model 10 0.85±0.03 0.95±0.03 0.97±0.17 1.89±0.16*△ 2.13±0.13**△

Table 2

Content of serum triacylglycerol in two groups at different time points ($\bar{x}$±s, mmol/L)"

Group n Triacylglycerol
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 0.35±0.05 0.41±0.04 0.45±0.13 0.61±0.04△ 0.84±0.10△
Model 10 0.37±0.06 0.43±0.01 0.47±0.03 0.64±0.05△ 1.09±0.03*△

Table 3

Content of serum low-density lipoprotein cholesterol in two groups at different time points ($\bar{x}$±s, mmol/L)"

Low-density lipoprotein cholesterol
Group n 0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 0.41±0.09 0.45±0.06 0.47±0.10 0.46±0.02 0.49±0.07
Model 10 0.40±0.07 0.51±0.03 0.57±0.04 0.99±0.09*△ 1.23±0.15**△

Table 4

Content of serum high-density lipoprotein cholesterol in two groups at different time points ($\bar{x}$±s, mmol/L)"

Group n High-density lipoprotein cholesterol
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 0.98±0.01 1.00±0.04 1.02±0.03 1.03±0.06 1.03±0.09
Model 10 0.99±0.02 0.97±0.03* 1.00±0.02 1.00±0.07 0.94±0.02*

Table 5

Content of serum tumor necrosis factor-α in two groups at different time points ($\bar{x}$±s, μg/mL)"

Group n Tumor necrosis factor-α
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 0.76±0.18 0.85±0.16 1.01±0.14 1.02±0.16 1.06±0.09
Model 10 0.82±0.13 1.67±0.11* 1.98±0.17*△ 2.48±0.19*△ 3.11±0.18**△

Table 6

Content of serum interleukin-6 in two groups at different time points ($\bar{x}$±s, ng/L)"

Group n Interleukin-6
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 101.23±19.15 98.23±18.49 111.48±12.84 93.64±15.49 113.88±10.48
Model 10 90.18±10.26 170.59±19.81* 210.88±22.59*△ 350.18±19.56**△ 420.26±22.56**△

Table 7

Content of serum leptin in two groups at different time points ($\bar{x}$±s, μg/L)"

Group n Leptin
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 4.82±0.21 5.22±0.33 5.23±0.36 5.39±0.62 5.60±0.61
Model 10 4.78±0.30 6.31±0.58* 6.37±0.71* 7.72±0.66*△ 9.03±0.69*△

Table 8

Content of plasma cyclic adenosine monophosphate in two groups at different time points ($\bar{x}$±s, pmol/L)"

Group n Plasma cyclic adenosine monophosphate
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 39.21±4.32 38.99±5.17 39.02±6.54 40.10±7.20 38.46±5.69
Model 10 40.19±4.23 41.24±5.94 51.28±5.66*△ 68.94±7.29*△ 72.11±6.1**△

Table 9

Content of plasma cyclic guanosine monophosphate in two groups at different time points ($\bar{x}$±s, pmol/L)"

Group n Plasma cyclic guanosine monophosphate
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 11.09±0.47 11.21±0.36 11.29±0.39 11.12±0.20 11.24±0.26
Model 10 11.06±0.79 11.53±0.41 9.14±1.01*△ 8.32±1.09*△ 7.23±1.10**△

Table 10

Ratio of cAMP to cGMP in two groups at different time points ($\bar{x}$±s)"

Group n cAMP/cGMP
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 3.02±0.57 3.25±0.67 3.19±0.59 3.38±0.70 3.40±0.66
Model 10 3.13±0.89 3.89±0.71 5.01±0.92* 7.99±0.98*△ 9.12±1.01**△

Table 11

Whole blood viscosity under high shear in two groups at different time points ($\bar{x}$±s, mPa·s)"

Group n Whole blood viscosity under high shear
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 5.88±0.15 5.89±0.12 5.89±0.17 5.90±0.13 5.92±0.11
Model 10 5.89±0.10 5.90±0.13 5.91±0.16 5.94±0.19 6.10±0.18*△

Table 12

Whole blood viscosity under low shear in two groups at different time points ($\bar{x}$±s, mPa·s)"

Group n Whole blood viscosity under low shear
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 12.78±0.11 12.92±0.14 12.04±0.12 13.04±0.33 13.22±0.21
Model 10 12.91±0.23 12.98±0.21 12.99±0.19 13.09±0.12 14.10±0.27*△

Table 13

Plasma viscosity in two groups at different time points ($\bar{x}$±s, mPa·s)"

Group n Plasma viscosity
0 week 6 weeks 8 weeks 10 weeks 12 weeks
Control 10 1.58±0.13 1.59±0.09 1.57±0.11 1.61±0.16 1.63±0.08
Model 10 1.61±0.09 1.62±0.08 1.59±0.13 1.64±0.06 1.79±0.04*△
[1] Liu Y, Xie M , Zhang Y. Development in syndromes of Chinese medicine for rat model of type 2 diabetes with insulin resistance. Zhongguo Shi Yan Fang Ji Xue Za Zhi. 2011 ; 17(14):127-131. Chinese with abstract in English.
doi: 10.3969/j.issn.1005-9903.2011.14.038
刘玥, 谢鸣, 张业 . 2型糖尿病胰岛素抵抗大鼠模型中医外观表征的变化.中国实验方剂学杂志. 2011; 17(14):127-131.
doi: 10.3969/j.issn.1005-9903.2011.14.038
[2] Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM . A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism. 2000; 49(11):1390-1394.
doi: 10.1053/meta.2000.17721 pmid: 11092499
[3] Zhang JC , Chen KJ. Combined disease with syndrome: clinical optimization mode of integrated Chinese and Western medicine. Shi Jie Zhong Yi Yao. 2006; ( 1):14-15. Chinese with abstract in English.
doi: 10.3969/j.issn.1673-7202.2006.01.006
张京春, 陈可冀 . 病证结合是中西医结合临床的最佳模式.世界中医药. 2006; ( 1):14-15.
doi: 10.3969/j.issn.1673-7202.2006.01.006
[4] Chai CZ, Kou JP, Zhu DN, Yan YQ , Yu BY. Thinking of current situation of animal model of tradition Chinese medicine combining disease and syndrome. Zhongguo Zhong Yao Za Zhi. 2009; 34(20) : 2673-2675. Chinese with abstract in English.
doi: 10.3969/j.issn.1005-5304.2010.01.003
柴程芝, 寇俊萍, 朱丹妮, 严永清, 余伯阳 . 关于病证结合动物模型研究现状的思考.中国中药杂志. 2009; 34(20) : 2673-2675.
doi: 10.3969/j.issn.1005-5304.2010.01.003
[5] Ji DC, Li CY. Making evaluation and prospects of integration of disease and syndrome animal models. Zhejiang Zhong Yi Yao Da Xue Xue Bao. 2010; 34(4):615-618. Chinese with abstract in English.
纪冬琛, 李昌煜 . 病证结合动物模型的制作、评价与展望.浙江中医药大学学报. 2010; 34(4):615-618.
[6] Wang SH , Wang WJ. Pathogenesis of insulin resistance and prevention and treatment strategy of integrated traditional Chinese and Western medicine. J Chin Integr Med. 2004; 2(1):14-16. Chinese with abstract in English.
王树海, 王文健 . 胰岛素抵抗的发病机制及中西医结合防治策略.中西医结合学报. 2004; 2(1):14-16.
[7] Lin L. Diabetology of integration of traditional Chinese and Western medicine. Beijing : China Medical Science Press. 1999: 106-108. Chinese.
林兰 . 中西医结合糖尿病学.北京: 中国医药科技出版社. 1999: 106-108.
[8] Zhang YQ, He GZ, Han Q, Kong XM, Li Y, Zeng PA, Zhang Y, Zhang QG , Zhou XS. Summary report of epidemiological investigation of Chinese medicine on 2 080 patients with diabetes. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi. 2004; 10(12):45-47. Chinese.
张延群, 和贵章, 韩清, 孔祥梅, 李瑛, 曾平安, 张勇, 张绮桂, 周旭生 . 2 080例糖尿病中医流行病学调研报告小结.中国中医基础医学杂志. 2004; 10(12):45-47.
[9] Chen SL, Lin L, Chu XY , Wang ZL. Correlation between syndrome differentiation of traditional Chinese medicine of type 2 diabetes and insulin resistance. Zhongguo Zhong Yi Yao Xin Xi Za Zhi. 2001; 8(6) : 49-51. Chinese.
doi: 10.3969/j.issn.1005-5304.2001.06.028
陈思兰, 林兰, 楚晓燕, 王兆礼 . 2型糖尿病中医辨证分型与胰岛素抵抗的相关性分析.中国中医药信息杂志. 2001; 8(6) : 49-51.
doi: 10.3969/j.issn.1005-5304.2001.06.028
[10] Xu CX, Ye WC, Hu YG. Syndrome differentiation and correlative analysis of 120 cases of type 2 diabetes mellitus. Shanghai Zhong Yi Yao Za Zhi. 2007 ; 41(6):34-36. Chinese with abstract in English.
doi: 10.3969/j.issn.1007-1334.2007.06.015
徐成兴, 叶伟成, 胡蕴刚 . 120例2型糖尿病患者的中医辨证分型及相关分析.上海中医药杂志. 2007; 41(6):34-36.
doi: 10.3969/j.issn.1007-1334.2007.06.015
[11] Wu Y , Li JL. Study on type 2 diabetes with syndrome of qi and yin deficiency. Zhong Yi Yao Xue Kan. 2003; 21(7):1080-1081. Chinese.
吴忆, 李敬林 . 气阴两虚2型糖尿病研究探要.中医药学刊. 2003; 21(7):1080-1081.
[12] Yan HF, MaJL, Zhu HH, Qu K, Qu F, FanXH, Bai J , Zeng XR. Clinical observation of correlation between vexing heat in the chest, plams and soles of yin deficiency syndrome and TNF-α, IL-1β or IL-6. Zhonghua Zhong Yi Yao Xue Kan. 2008; 26(2):293-295. Chinese.
严惠芳, 马居里, 朱海慧, 屈凯, 曲锋, 樊雪红, 白洁, 曾晓荣 . 阴虚证五心烦热与TNF-α、IL-1β、IL-6相关性的临床观察.中华中医药学刊. 2008; 26(2):293-295.
[13] Zhou LB, Li M, Li XY , Tong XL. Basic biology research on different types of syndrome of obese type 2 diabetes. Zhonghua Zhong Yi Yao Za Zhi. 2009 ; 24(8) : 1023-1027. Chinese with abstract in English.
周丽波, 李敏, 李修洋, 仝小林 . 肥胖2型糖尿病患者不同中医证型生物学基础研究.中华中医药杂志. 2009; 24(8) : 1023-1027.
[14] Wang H, Ma WM, Chen XT, Du YL, Chen ZH. Study of the relationship between leptin, IGF-I and syndrome of yin deficiency with excessive heat or dual deficiency of qi and yin of type 2 diabetes. Zhongguo Zhong Yi Yao Ke Ji. 2006 ; 13(4):211-212. Chinese.
王晖, 马伟明, 陈笑腾, 杜玉琳, 陈振浩 . 痩素、胰岛素样生长因子-I与阴虚热盛、气阴两虚型2型糖尿病关系的探讨.中国中医药科技. 2006; 13(4):211-212.
[15] Zhou GY, Wu XP, Heng XP , Weng L. Correlation between type 2 diabetes of dual deficiency of qi and yin and insulin resistance. Fujian Zhong Yi Yao. 2000; 31(2) : 7~ 8. Chinese.
周国英, 武雪萍, 衡先培, 翁玲 . 2型糖尿病气阴两虚证与胰岛素抵抗的相关性研究.福建中医药. 2000; 31(2) : 7~ 8.
[16] Yin JG. Relationship of functions of cAMP and cGMP in antagonizing metabolic regulation and yin and yang of Chinese medicine. Shaanxi Zhong Yi Xue Yuan Xue Bao. 1987; 10(1):51-54. Chinese.
阴建国 . cAMP和cGMP的拮抗代谢调节与中医“阴阳”关系.陕西中医学院学报. 1987; 10(1):51-54.
[17] Zhang P , Hong BY. Mechanism in dynamic balance of cAMP and cGMP in human body. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Jin Zhan. 1985; ( 3):46-48. Chinese.
张鹏, 洪宝源 . 人体内cAMP与cGMP动态平衡机理的探讨.生物化学与生物物理进展. 1985; ( 3):46-48.
[18] Shao BY, Jin ZX , Wu HH. Clinical significance of changes in contents of plasma cAMP and cGMP of patients with type 2 diabetes. Lin Chuang Nei Ke Za Zhi. 1984; 1(1):41-42. Chinese.
邵丙扬, 金之欣, 吴恒慧 . 糖尿病患者血浆cAMP和 cGMP的变化及其临床意义.临床内科杂志. 1984; 1(1):41-42.
[19] Feng YX, Dong YH, Pang LN, Shen SX, Zhang Y , Cheng LX. The effect of type 2 diabetes mellitus on bone metabolism and the related hormones. Zhongguo Tang Niao Bing Za Zhi. 1999 ; 7(5) : 273-276. Chinese with abstract in English.
冯玉欣, 董砚虎, 逄力男, 沈守祥, 张奕, 程丽霞 . 2型糖尿病对骨代谢及相关激素的影响.中国糖尿病杂志. 1999; 7(5) : 273-276.
[20] Zhao L, Wei HF, Zhang L, Li YL , Li L. Study on biological basis of phlegm and blood stasis syndromes in TCM. Zhonghua Zhong Yi Yao Za Zhi. 2008; 23(8):680-683. Chinese with abstract in English.
赵玲, 魏海峰, 张丽, 李雅莉, 李林 . 中医痰浊血瘀证候的生物学基础研究.中华中医药杂志. 2008; 23(8):680-683.
[21] Xu Y. Ideas and methods of traditional Chinese medicine in treating metabolic syndrome. Zhong Yi Za Zhi. 2003; 44(4) : 301-302. Chinese.
徐远 . 中医治疗代谢综合征的思路与方法.中医杂志. 2003; 44(4) : 301-302.
[22] Han LB, Yang HM, Cui HX , Liu JF. TCM syndromes of type 2 diabetic dyslipidemia. Beijing Zhong Yi Yao Da Xue Xue Bao. 2010; 33(5):358-360. Chinese with abstract in English.
韩丽蓓, 杨惠民, 崔红霞, 刘金凤 . 2型糖尿病血脂异常的中医证候研究.北京中医药大学学报. 2010; 33(5):358-360.
[23] Chen KJ, Li LD, Weng WL. Research on blood stasis syndrome and activating blood circulation and eliminating stasis method. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi. 2005; 3(1):1-2. Chinese.
陈可冀, 李连达, 翁维良 . 血瘀证与活血化瘀研究.中西医结合心脑血管病杂志. 2005; 3(1):1-2.
[24] Shi DZ , Chen KJ. Prospects of preventing thrombosis by activating blood circulation and eliminating stasis drugs. Zhong Yi Za Zhi. 1993; 34(5):308-310. Chinese.
史大卓, 陈可冀 . 活血化瘀方药防治血栓形成的前景. 中医杂志. 1993; 34(5):308-310.
[25] Tang YX . Correlation between type 2 diabetes mellitus of insulin resistance and phlegm, blood stasis and toxin of traditional Chinese medicine. Zhongguo Yi Yao Xue Bao. 2004; . Chinese.
唐迎香 . 2型糖尿病胰岛素抵抗与中医痰瘀毒相关性研究.中国医药学报. 2004; 19(4):237-239.
[26] Shi SZ, Chen JQ, Zhang MH, Shi ZY, Deng SZ, He WT, Ni ZM, Xu XF . Macroscopic and microscopic research on blood stasis syndrome of diabetes. Zhong Yi ZaZhi. 1997; 38(4):233-235. Chinese.
施赛珠, 陈剑秋, 张茂华, 石志芸, 邓守贞, 何婉婷, 倪赞明, 许小风 . 宏观与微观相结合研究糖尿病血瘀证.中医杂志. 1997; 38(4):233-235.
[27] Chen LG, Ma M, Qu Y , Zhang CL. Reserch progress of blood stasis syndrome of diabetes. Zhonghua Zhong Yi Yao Za Zhi. 2005; 20(2):114-116. Chinese.
doi: 10.3969/j.issn.1673-1727.2005.02.017
陈利国, 马民, 屈援, 张春玲 . 糖尿病血瘀证研究进展.中华中医药杂志. 2005; 20(2):114-116.
doi: 10.3969/j.issn.1673-1727.2005.02.017
[1] Theocharis Koufakis, Kalliopi Kotsa, Nikolaos Papanas. Remission of type 2 diabetes depends on prompt comprehensive lifestyle changes upon diagnosis: How can this “Road to Damascus” experience be supported?. Journal of Integrative Medicine, 2022, 20(4): 288-291.
[2] Zeinab Vafaeipour, Bibi Marjan Razavi, Hossein Hosseinzadeh. Effects of turmeric (Curcuma longa) and its constituent (curcumin) on the metabolic syndrome: An updated review. Journal of Integrative Medicine, 2022, 20(3): 193-203.
[3] Shu-yi Chen, Qun-wei Chen, Liu-mei Shou, Hong Pan, Shan-ming Ruan, Zhe-hao Liang, Qi-jin Shu. Stevens-Johnson syndrome/toxic epidermal necrolysis successfully treated with Chinese herbal medicine Pi-Yan-Ning: A case report. Journal of Integrative Medicine, 2021, 19(6): 555-560.
[4] Liang Ding, Xin-you Zhang, Di-yao Wu, Meng-ling Liu. Application of an extreme learning machine network with particle swarm optimization in syndrome classification of primary liver cancer. Journal of Integrative Medicine, 2021, 19(5): 395-407.
[5] Riska Siregar, Aris Setyawan, Syahruramdhani Syahruramdhani. A model to standardize safety and quality of care for cupping therapy. Journal of Integrative Medicine, 2021, 19(4): 327-332.
[6] Yunita Sari, Akhyarul Anam, Annas Sumeru, Eman Sutrisna. The knowledge, attitude, practice and predictors of complementary and alternative medicine use among type 2 diabetes mellitus patients in Indonesia. Journal of Integrative Medicine, 2021, 19(4): 347-353.
[7] Shu-jun Wei, Qing-man He, Qing Zhang, Kang-hua Fu, Ruo-lan Li, Wei Peng, Yong-xiang Gao. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review. Journal of Integrative Medicine, 2021, 19(3): 191-202.
[8] Si-qi Tang, Yun-liang Wang, Zi-ye Xie, Yang Zhang, Yi Guo, Kang-li Gao, Tang-you Mao, Chun-e Xie, Jun-xiang Li, Xiao-yan Gao. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome. Journal of Integrative Medicine, 2021, 19(3): 274-281.
[9] Bing-rong Li, Shi-yun Shao, Long Yuan, Ru Jia, Jian Sun, Qing Ji, Hua Sui, Li-hong Zhou, Yi Zhang, Hui Liu, Qi Li, Yan Wang, Bi-meng Zhang. Effects of mild moxibustion on intestinal microbiome and NLRP3 inflammasome in rats with 5-fluorouracil-induced intestinal mucositis. Journal of Integrative Medicine, 2021, 19(2): 144-157.
[10] Dastan M. Khoshnaw, Abhijit A. Ghadge. Yoga as a complementary therapy for metabolic syndrome: A narrative review. Journal of Integrative Medicine, 2021, 19(1): 6-12.
[11] Pukar Khanal, Basanagouda M. Patil. Integration of network and experimental pharmacology to decipher the antidiabetic action of Duranta repens L.. Journal of Integrative Medicine, 2021, 19(1): 66-77.
[12] Baoyi Shao, Saiying Hou, Yuenyan Chan, Changchun Shao, Lixing Lao. Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: A case report. Journal of Integrative Medicine, 2021, 19(1): 85-88.
[13] Abdulhakim Abubakar, Abdullahi Balarabe Nazifi, Idris Mohammed Maje, Yusuf Tanko, Joseph Akpojo Anuka, Ezzeldin Mukthar Abdurahman. Antihyperglycaemic activity of ethylacetate extract of Chlorophytum alismifolium in type 2 diabetes: The involvement of peroxisome proliferator-activated receptor-γ and dipeptidyl peptidase-4. Journal of Integrative Medicine, 2021, 19(1): 78-84.
[14] . External application of two unrestricted herbal medicines to treat costochondritis in a young collegiate athlete: A case report. Journal of Integrative Medicine, 2020, 18(5): 450-454.
[15] Johannes Loeser, Brigitte Layer, Christopher Plata, Klaus-Maria Perrar, Tim Hucho, Rebecca Kulbida. Hirudotherapy attenuates arthritic pain in patients with various chronic pain syndromes: A retrospective analysis. Journal of Integrative Medicine, 2020, 18(5): 425-433.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Wei Zhang, Xiang-feng Lu, Xiao-mei Zhang, Jian-jun Wu, Liang-duo Jiang. A rat model of pulmonary fibrosis induced by infusing bleomycin quickly through tracheal intubation. Journal of Chinese Integrative Medicine, 2008, 6(1): 60-67
[5] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[6] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[7] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[8] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[9] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[10] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3